

2022 Spring Conference

Wed 20th - Fri 22nd April
Manchester Central, Manchester



Welcome



Dr Laura Waters
Chair,
British HIV Association
(BHIVA)

A HUGE & HEARTFELT welcome to this year's BHIVA Spring Conference in Manchester!

We are very excited to hold our Spring Conference as a face-to-face gathering for the first time since 2019 and after all the positive feedback about the last Autumn meeting we think you will be too!

We have created a programme to cover a range of important HIV-related topics - please see the programme pages for a full schedule of topics and timings.

In addition, in response to feedback, we're replacing the usual gala dinner with a more relaxed social reception – please join us if you can.

Massive thanks to the speakers and committee members, especially conferences chair Dr Nicky Mackie, whose hard work has made this meeting possible. Finally, thank you to our sponsors for their continued and generous support of BHIVA, which assists greatly with covering of the costs of running this conference. We hope you enjoy the programme, find it educational and FUN!

Dr Laura Waters
Chair, British HIV Association (BHIVA)



Contents

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and catering areas.

BHIVA committees	5
Conference information	6
Social events	9
Scholarships and awards	10
Spring Conference Programme	11
Poster abstracts	16
Programme of satellite symposia and sponsors' workshops	24
Speakers biographies	26
Exhibition floor plan and exhibitors	37
Sponsors and exhibitor biographies	38
Speakers & conflicts of interest	46

BHIVA Executive Committee

Chair

Dr Laura Waters, Mortimer Market Centre,
London

Vice Chair

Professor Caroline Sabin, University College
London

Honorary Treasurer

Dr Iain Reeves, Homerton University Hospital,
London

Honorary Secretary

Professor Yvonne Gilleece, Brighton & Sussex
Medical School and University Hospitals Sussex
NHS Foundation Trust

MEMBERS

Dr Tristan Barber, Royal Free London NHS Trust

Dr David Chadwick, James Cook University
Hospital, Middlesbrough

Dr Daniel Clutterbuck, NHS Lothian

Dr Ashini Fox, Nottingham University Hospital

Dr Ranjababu Kulasegaram, St Thomas'
Hospital, London

Dr Nick LARBALÉSTIER, Guy's and St. Thomas'
NHS Foundation Trust

Dr Nicola Mackie, Imperial College Healthcare
NHS Trust, London

Dr Jonathan Underwood, University Hospital of
Wales

Dr Clare van Halsema, Manchester University
NHS Foundation Trust

New Consultant Doctors' Representative

Dr Rebecca Metcalfe, NHS Greater Glasgow
and Clyde

Trainee Doctor's Representative

Dr Manik Kohli, Central and North West London
NHS Foundation Trust

UK-CAB Representative

Ms Jo Josh, UK Community Advisory Board

Financial Expert Trustee

Ms Paula Bibby

BHIVA Conferences Subcommittee

Chair

Dr Nicola Mackie, Imperial College Healthcare
NHS Trust

Vice Chair

Dr Matthew Page, University Hospitals
Birmingham NHS Foundation Trust

Members

Mr Asim Ali, Guys & St Thomas' NHS
Foundation Trust

Dr Tristan Barber, Royal Free London NHS
Foundation Trust

Professor Yvonne Gilleece, Brighton & Sussex
Medical School and University Hospitals Sussex
NHS Foundation Trust

Dr Ranjababu Kulasegaram, Guys & St Thomas'
NHS Foundation Trust, London

Dr Farai Nyatsanza, Cambridgeshire Community
Services NHS Trust

Dr Iain Reeves, Homerton University Hospital
NHS Foundation Trust, London

Professor Caroline Sabin, University College
London

Dr Laura Waters, Central and North West
London NHS Foundation Trust

Dr Clare van Halsema, Manchester University
NHS Foundation Trust

UK-CAB Representative

Ms Jo Josh, UK Community Advisory Board

Local Host

Dr Clare van Halsema, Manchester University
NHS Foundation Trust

Conference Information

Venue

Manchester Central
Petersfield, Manchester, M2 3GX
T: 0161 834 2700
W: manchestercentral.co.uk

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Exhibition Opening Times

Wednesday 20th April	08:00 – 19:00 (incl. Drinks Reception)
Thursday 21st April	08:00 – 17:45
Friday 22nd April	08:00 – 14:10

Registration

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence. The registration desk is located in the Charter Foyer and will be open during the following hours:

Wednesday 20th April	08:00 – 18:30
Thursday 21st April	07:30 – 18:00
Friday 22nd April	07:30 – 14:30

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas.

Conference Sessions

Plenary sessions, lunchtime workshops and the oral abstract sessions will take place in the Charter Suites. Doors will open 15 minutes prior to the lunchtime workshops and places are available on a first-come, first-served basis. No separate lunch will be provided for delegates attending workshops, however lunch will be available in the Exhibition Hall for the full duration of the lunch period.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 139444. The entire conference has been

allocated 19 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

Social events

There are two social events: a Welcome Reception (Wednesday) to be held at Manchester Central and a Social evening (Thursday) to be held at The Refuge, Oxford Street, Manchester. Tickets are required to gain entry to the Social Evening on Thursday. Please refer to page 9 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Poster presentations

Posters will be displayed in Central Hall 1. All poster boards will be numbered, and poster presenters should use the board displaying the number allocated to their poster.

Posters will be judged during the welcome reception 18:00 – 19:00 Wednesday 20th April, and poster authors are encouraged to stand by their posters during this time. A selection of poster authors will be invited to present their research in the Best Poster Session 10:00 Friday 22nd April and poster prizes will be presented in the Closing Session of the same day.

Speaker preview room

All presenters are reminded to ensure they visit the speaker preview room at least 3 hours in advance of

their talk to check and sign off that we have the most up to date version of their slides. Speakers will be able to make final changes with the technicians here but will not be able to change their presentation in the auditorium or present from their own laptop.

The Speakers' Preview Room is located in the Organisers Office 3 located in the Exhibition Hall, Central Hall 1.

WiFi

Free WiFi access is available throughout the conference venue.

Cloakroom

A manned cloakroom is available onsite at the venue. All belongings are left at the owner's risk. The British HIV Association does not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

Filming and photography

Please note that all sessions held in the Charter Suites will be filmed and uploaded to the BHIVA website following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published in BHIVA publications or on the BHIVA website and on BHIVA's social media pages.

Liability and insurance

The Meeting Secretariat and Organisers cannot accept liability for personal accidents or loss or damage to private property of participants either during or indirectly arising from the BHIVA Spring Conference.

Social Media

Follow BHIVA on social media. #BHIVA2022



British HIV Association



BritishHIVAssociation



@BritishHIVAssoc

Safety measures

The safety of delegates is our priority and we have worked with Manchester Central to ensure we make the conference as safe as possible for everyone.

We are still taking measures including the provision of hand sanitiser and social distancing markers, we encourage the wearing of face covering in crowded areas where social distancing may not be possible.

Face masks will be available from the registration desk throughout the conference if required. Whilst LFT testing is no longer a legal requirement we would like to encourage you to test prior to traveling to the conference. If you test positive or have any COVID symptoms please do not attend the conference and contact the secretariat to discuss the cancellation of your place.

We have also taken the below steps to ensure we provide a safe conference for all.

- Hand- sanitisers will be provided around the venue
- The venue ventilation operates at 100% fresh air with no recirculation of air from the conference space.
- The cleaning of the toilets will be increased daily and we are taking measures to reduce queuing at the toilets.


We encourage all attendees to use contactless payments for any catering, and car park payments.



HANDS



FACE



SPACE

Social Events

BHIVA Welcome Reception

Please join us for the Welcome Reception on
Wednesday 20th April 2022

This event will take place from: **6pm**

In the: **Conference Venue, Manchester Central**

Please join us for a drink and some nibbles after our first Day at Conference.
This event is free to attend.

BHIVA Social Evening

Please join us for the BHIVA Social Evening on
Thursday 21st April 2022

This event will take place from: **7pm**

At: **The Refuge, Oxford Street, Manchester, M60 7HA**

The evening will be an informal opportunity for people to come together, with food, welcome drinks, music and dancing! (and a cash bar operating all evening).

Tickets cost: **£25 per person** and can be purchased in advance or at the registration desk.



Scholarships and Awards

The BHIVA Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 22nd April.

The BHIVA Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 22nd April.

Chloe Orkin and Martin Fisher Awards

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 22nd April.

The BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA Lunchtime Clinico-pathological case presentations sessions. The prizes will be presented at the Prizes and Awards Ceremony on Friday 22nd April.

Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 22nd April.

Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. A rosette will be awarded to the top 15 posters after the poster judging session during the Welcome Reception. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 22nd April.

BHIVA Science Scholarships

Science Scholarships have been awarded up to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees and a contribution towards travel and the cost of accommodation for up to three nights are covered by BHIVA.

BHIVA Community Registration Support

BHIVA have supported up to 50 registration places from community and affiliated organisations in order to assist with attendance at conference.

BHIVA Community Scholarships

BHIVA Community Scholarships have been awarded to up to 10 UK-based community registrants. All registration fees and a contribution towards accommodation for up to three nights have been covered by BHIVA. In addition a contribution is offered by BHIVA towards travel expenses.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 10 delegates who are either retired, not working or employed in a part-time capacity. Places are also allocated to students involved in full-time undergraduate or post-graduate work. The scholarship covers the conference registration fee.

Scientific Programme

WEDNESDAY 20TH APRIL 2022

- 09:00 - 09:15 **Welcome & Introduction by the Chair of BHIVA**
Charter Suite 2 & 3
Dr Laura Waters, Mortimer Market Centre, London, UK
- 09:15 - 09:55 **Plenary: update on opportunistic infections Charter Suite 2 & 3**
Chair: Dr Clare van Halsema, Manchester University NHS Foundation Trust, UK; Manchester University NHS Foundation Trust, UK
Dr Angela Bailey, Buckinghamshire Healthcare NHS Trust, UK
- 09:55 - 10:35 **ART update: strategies & drugs Charter Suite 2 & 3**
Chair: Dr Dan Clutterbuck, Royal Infirmary of Edinburgh, UK
Dr Laura Waters, Mortimer Market Centre, London, UK
- 10:35 - 11:05 *Break* **Central Hall 1**
- 11:05 - 12:00 **COVID-19 Update Charter Suite 2 & 3**
Chair: Dr Jonathan Underwood, University Hospital of Wales, UK
Co-chair: Mr Asim Ali, Guys & St Thomas' NHS Foundation Trust, UK
- The Challenge of managing post-acute COVID-19**
Dr Swapna Mandal Royal Free London NHS Foundation Trust, UK
- Covid treatment update**
Dr Alison Uriel, Manchester University Foundation Trust, UK
- COVID-19 immunity and vaccine efficacy in people living with HIV**
Dr Dimitra Peppas University College London, UK
- 12:00 - 13:00 **Oral Session 1**
Charter Suite 2 & 3
Chair: Professor Caroline Sabin, University College London, UK
Co-chair: Dr Alex Langrish, UK
- O1 Self start HOME HIV Post exposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy: A RCT**
Dr Julie Fox, Guys and St Thomas' NHS Trust, UK
- O2 HIV testing outcomes amongst pre-exposure HIV prophylaxis (PrEP) users accessing a regional online sexual health service (e-SHS)**
Molly Dickinson, Chelsea and Westminster Hospital, London, UK
- O3 Experiences of PrEP stigma and discrimination in healthcare settings in the UK among a community sample of PrEP users**
Amber Newbigging-Lister, UK Health Security Agency, UK
- O4 Driving towards zero, bringing HIV testing and prevention to migrant communities across London**
Poppy Vernon, METRO Charity, UK
- O5 Estimating the number of people living with transmissible HIV in England in 2020**
Dr Veronique Martin, UK Health Security Agency, UK
- 13:00 - 14:15 *Lunch & Exhibition* **Central Hall 1**
- 13:15 - 14:00 **Parallel workshops**
Achieving the HIV Action Plan Goals: Building closer ties between HIV Prevention England and clinicians
Charter Suite 4
Chair: Dr Michael Brady, Terrence Higgins Trust and Kings College Hospital, UK
Alex Sparrowhawk, Terrence Higgins Trust, UK
Professor Matt Phillips, North Cumbria Integrated Care NHS Foundation Trust, UK
Anne Glew, The Brunswick Centre
Anthony Harrison-West, Renaissance UK
- Sponsor's workshop – Gilead Sciences**
Charter Suite 1

WEDNESDAY 20TH APRIL 2022

	<p>SWIFT workshop: WONDER, Women and Bones Charter Suite 2 & 3</p> <p>Professor Yvonne Gilleece, University Hospitals Sussex NHS Foundation Trust, UK</p> <p>Ms Fungai Murau, Independent Consultant, UK</p> <p>Hajra Okhai, University College London, UK</p>	17:05 - 18:00	<p>Pregnancy & reproductive health updates/conundrums Charter Suite 2 & 3</p> <p>Chair: Dr Rebecca Metcalfe, NHS Greater Glasgow & Clyde, UK</p> <p>Co-chair: Rebecca Mbewe, Positively UK</p> <p>Pregnancy/breastfeeding update Dr Laura Byrne, St George's University Hospitals NHS Foundation Trust, UK</p> <p>Contraceptive Choices - Transgender Patient Dr Louise Melvin, Sandyford Sexual Health Service, UK</p> <p>Post-reproductive health in women living with HIV Dr Shema Tariq, University College London/Mortimer Market Centre, UK</p> <p>Panel Discussion Members Professor Yvonne Gilleece, University Hospitals Sussex NHS Foundation Trust, UK & Bakita Kasadha, University of Oxford, UK</p>
14:15 - 15:15	<p>Sponsored Satellite Symposium – ViiV Healthcare Charter Suite 2 & 3</p>		
15:15 - 16:15	<p>Oral Session 2 Charter Suite 2 & 3</p> <p>Chair: Professor Chloe Orkin, Queen Mary university of London, UK</p> <p>Co-chair: Dr Fiona Windebank, Leeds Teaching Hospitals NHS Trust, UK</p> <p>O6 Mortality among people with HIV in the UK in 2020: findings from the National HIV Mortality Review Dr Sara Croxford, UK Health Security Agency, UK</p> <p>O7 Improving short-term mortality of people living with HIV admitted to the Intensive Care Unit: A 20-year study (2000-2019) Dr Tanmay Kanitkar, Royal Free Hospital, UK</p> <p>O8 Addressing a significant health inequality: a project to re-engage patients lost to HIV follow up Dr Kate Childs, King's College Hospital NHS Foundation Trust, UK</p> <p>O9 Investigating the pregnancy and post-partum health experiences of women living with HIV: The NESTOR study Rebecca Cooper, Sheffield Medical School, UK</p> <p>O10 Pregnancy characteristics and outcomes of women with vertically-acquired HIV in the UK Helen Peters, UCL Great Ormond Street Institute of Child Health, UK</p>	18:00	<p><i>Close, poster viewing & drinks reception</i> Central Hall 1</p>
16:15 - 16:35	<i>Break</i> Central Hall 1		
16:35 - 17:05	<p>M184V: does it matter? Charter Suite 2 & 3</p> <p>Chair: Professor Anna Maria Geretti, University of Rome Tor Vergata, Rome, Italy & King's College London, London, UK</p> <p>Professor Chloe Orkin, Queen Mary University of London, UK</p>		

THURSDAY 21ST APRIL 2022

- 08:00 - 08:45 **Sponsored Symposium slot – Janssen Charter Suite 2 & 3**
- 08:50 - 09:30 **Malignancy update Charter Suite 2 & 3**
Chair: Dr Nick LARBALÉSTIER, Guy's and St Thomas' NHS Foundation Trust, UK
Professor Stéphane de Wit, Saint-Pierre University Hospital, Belgium
- 09:30 - 10:10 **What is new about hepatitis B? From novel biomarkers to innovative cure strategies Charter Suite 2 & 3**
Chair: Dr Ranjababu Kulasegaram, Guy's and St Thomas' NHS Foundation Trust, UK
Professor Anna Maria Geretti, University of Rome Tor Vergata, Rome, Italy & King's College London, London, UK
- 10:10 - 10:30 *Break* **Central Hall 1**
- 10:30 - 12:00 **AUDIT Session Charter Suite 2 & 3**
Chair: Dr Iain Reeves, Homerton University Hospital, UK
Co-chair: : Dr Emily Cheserem, North Middlesex University Hospital, UK
A national audit of the management of HIV-2 in adults in the UK
Dr Maya Tickell-Painter, Manchester Foundation Trust, UK
Multi-drug resistant HIV 2: let's think outside the box
Dr Athavan Umaipalan, Barking, Havering & Redbridge NHS Trust, UK
European perspective on BHIVA Audit/Standards
Professor. Dr Jürgen Rockstroh, University Hospital Bonn, Germany
Audit reflections
Dr Hilary Curtis, Clinical Audit Co-ordinator BHIVA, UK
- 12:00 - 13:00 **Oral Session 3**
Chair: Dr Chris Ward, The Northern Contraception, Sexual Health & HIV Service, UK
Co-chair: Dr Cristina Fernandez, Manchester University NHS Foundation Trust, UK
Charter Suite 2 & 3
O11 Inflammatory biomarker clusters based on protein biomarkers measured in people living with and without HIV
Nicholas Bakewell, University College London, UK
- O12 Exploring frailty and frailty screening for older people living with HIV**
Natalie St Clair-Sullivan, Brighton and Sussex Medical School, UK
O13 Anticholinergic medications associated with falls and frailty in people with HIV
Dr Jessica Doctor, Guy's and St Thomas' Hospital, UK
O14 Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
Dr Georgina Keogh, Chelsea & Westminster Hospital, UK
O15 Closing the circle: use of a data visualisation application (Qlik Sense®) to support quality improvement in HIV services
Dr Michael Butler, Imperial College Healthcare NHS Trust, UK
- 13:00 - 14:15 *Lunch & Exhibition* **Central Hall 1**
- 13:15 - 14:00 **Parallel workshops UK Community Advisory Board (UK-CAB) Workshop - The future of treatment? What people with HIV think about injectables Charter Suite 2 & 3**
Chair: Jo Josh, UK-CAB Steering Group
Grant Sugden, Waverley Care, UK
Josh Wharton, George House Trust, UK
Dr Chitra Sharma Babu, Manchester NHS Foundation Trust, UK
Fast-Track Cities update Charter Suite 4
Chairs: Dr Orla McQuillan, Northern Sexual Health, Manchester Foundation Trust
Ms Victoria Morris, Greater Manchester Health and Social Care Partnership
Fast-Track Cities as a leveraging tool for local innovations and an instrument of international solidarity
Mr Bertrand Audoin, International Association of Providers of AIDS Care
Fast-Track Cities: A Greater Manchester perspective, the importance of collaborative leadership
Mr Rob Cookson, LGBT Foundation
Testing the way to join elimination of HIV and Hepatitis C
Dr F Javier Vilar, North Manchester General Hospital, Manchester Foundation Trust

THURSDAY 21ST APRIL 2022

	<p>HIV Medicine workshop: Improving your publication success rate Charter Suite 1 Professor Caroline Sabin, University College London, UK Dr Laura Waters, Mortimer Markers Centre, London, UK Professor Jürgen Rockstroh, University Hospital Bonn, Germany</p>	16:35 - 17:45	<p>HIV and mortality in the current climate Charter Suite 2 & 3 Chairs: Dr David Chadwick, James Cook University Hospital, UK and Professor Robert Miller, CNWL/RFH/UCL, UK SpR case Dr Erica Pool, Mortimer Market Centre / UCL, UK Posthumous disclosure Professor Matt Phillips, North Cumbria Integrated Care NHS Foundation Trust, UK Death certification – facts and practicalities Professor Sebastian Lucas, Guy's & St Thomas' NHS Foundation Trust, UK Defining and monitoring preventable HIV-related mortality Dr Sara Croxford, Principal Scientist, UK Health Security Agency, UK</p>
14:15 - 15:15	<p>Sponsored Satellite Symposium – Gilead Sciences Charter Suite 2 & 3</p>		
15:15 - 16:15	<p>Oral Session 4 Charter Suite 2 & 3 Chair: Dr Clare van Halsema, Manchester University NHS Foundation Trust, UK Co-chair: Dr Manik Kohli, Mortimer Market Centre, London O16 Incidence of Metabolic Complications Among Treatment-naïve Adults Living With HIV-1 Randomised to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF After 3 Years Professor Chloe Orkin, Queen Mary University of London, UK O17 Safety profile of cabotegravir + rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies Dr Paul D. Benn, ViiV Healthcare, UK O18 The acceptability of offering rapid antiretroviral therapy to people living with HIV in East London: A qualitative study Dr Rageshri Dhairyawan, Barts Health NHS Trust, UK O19 HIV and mental health: improving generic NHS talking therapy services for people living with HIV in England Calum Douglas, National AIDS Trust, UK O20 Rebuilding the missing link to the Fourth 90: Addressing the mental health needs of an urban population of people living with HIV in a Greater London clinic Bonaventure Carl De Souza, Croydon University Hospital, UK</p>	17:45 19:00	<p>Close BHIVA Social Evening The Refuge, Oxford Street, Manchester (ticket only)</p>
16:15 - 16:35	<p>Break Central Hall 1</p>		

FRIDAY 22ND APRIL 2022

<p>08:00 - 09:00 Themed Poster session Charter Suite 1 Chairs: Dr Alan Winston, Imperial College London, UK Dr Douglas Fink, University College London, UK Posters TP01-TP08</p> <p>09:00 - 10:00 Chronic Pain Session Charter Suite 2 & 3 Chair: Dr Ashini Fox, Nottingham University Hospitals Trust, UK Co-chair: Jo Josh, UK-CAB, UK Psychosocial factors associated with chronic pain and its management in people living with HIV Dr Whitney Scott, King's College London/Guy's & St Thomas' NHS Foundation Trust, UK Clinical Management of chronic pain Dr Harriet Kemp, Imperial College Healthcare NHS Trust, UK</p> <p>10:00 - 10:55 Best poster session Charter Suite 2 & 3 Chair: Dr Ranjababu Kulasegaram, Guys & St Thomas' NHS Foundation Trust, UK Co-chair: Dr Jozef Shaw, Barts Health NHS Trust, UK</p> <p>10:55 - 11:15 <i>Break</i> Central Hall 1</p> <p>11:15 - 12:15 Sponsored Satellite Symposium – MSD Charter Suite 2 & 3</p> <p>12:15 - 13:00 Science Session (Brian Gazzard Lecture) Charter Suite 2 & 3 Chair: Dr Tristan Barber, Royal Free London NHS Foundation Trust, UK Co-chair: Dr Matthew Page, University Hospitals Birmingham NHS Foundation Trust, UK HIV pathogenesis & the role of the microbiome Dr Roger Paredes, Germans Trias i Pujol University Hospital/Irsi Caixa, Spain Inflammation & the role of ART Dr Jose Arribas, La Paz University Hospital, Spain</p> <p>13:00 - 14:10 <i>Lunch & Exhibition</i> Central Hall 1</p>	<p>13:15 - 14:00 Parallel workshops Adverse Childhood Experiences and their impact on Adult HIV Care Charter Suite 4 Chairs: Katie Warburton & Dr Amanda Williams, CHIVA, UK Dr Caroline Foster, Imperial College Healthcare NHS Trust, UK Dr Caroline Johnson, Imperial College Healthcare NHS Trust, UK & young adult speakers from CHIVA providing lived experiences Sponsor's Lunchtime Workshop – ViiV Healthcare Charter Suite 2 & 3 Living Well with HIV – personalising multiple long term condition management Charter Suite 1 Chair: Dr Tristan Barber, Royal Free London NHS Foundation Trust, UK Co-chair: Yvonne Richards, George House Trust, UK Jim Fielder, Terrence Higgins Trust, UK Dr Daniella Chilton, Guy's and St Thomas' NHS Foundation Trust, UK Dr Howell Jones, Royal Free London NHS Foundation Trust, UK Dr Fiona Marra, NHS Greater Glasgow and Clyde, and University of Liverpool,, UK</p> <p>14:10 - 15:00 Guidelines/Position Statements Charter Suite 2 & 3 Chair: Dr Laura Waters, Mortimer Market Centre, London, UK Co-chair: Dr Alexandra Maxwell, Sandyford Glasgow, UK ART Guidelines Dr John Walsh, Imperial College Healthcare NHS Trust, UK HIV, disclosure & the law Professor Matt Phillips, North Cumbria Integrated Care NHS Foundation Trust, UK</p> <p>15:00 - 16:00 Clinico-pathological case presentations Charter Suite 2 & 3 Chairs: Dr Ula Mahadeva, Guy's & St Thomas' NHS Foundation Trust, UK Professor Mark Bower, Chelsea and Westminster Hospital, UK Dr Alec Bonington, North Manchester General Hospital, UK</p> <p>16:00 Awards and closing remarks Charter Suite 2 & 3 Dr Laura Waters, Mortimer Market Centre, London, UK</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Poster Abstracts

ANTIRETROVIRALS: EFFICACY, INTERACTIONS & PHARMACOKINETICS

P001

Two years experience with doravirine

Dr Rachel Pringle, North Manchester General Hospital, UK

P002

Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV

Tanmay Kaniakar, Royal Free Hospital, UK

P003

Approaches to Optimise Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial

Cindy Elliott, Gilead Sciences Ltd., UK

P004

Lenacapavir as part of a combination regimen in treatment naïve people living with HIV: Week 54 results

Ross Hamilton-Shaw, Gilead Sciences Ltd., UK

P005

In Vitro Forgiveness of Oral and Long-Acting INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence

Gagandeep Gohlar, Gilead Sciences Ltd., UK

P006

Long acting lenacapavir in people with multi-drug resistant HIV-1: Week 52 results

Samm Kabagambe, Gilead Sciences Ltd., UK

P007

History of drug resistance mutations and virologic outcomes for 2-drug regimens - data from combine-2

Dr. Cristina Mussini, University of Modena and Reggio Emilia, Italy

P008

Top Practices for Implementing Cabotegravir (CAB) and Rilpivirine (RPV) Long-acting (LA) in European Clinics

Dr. Julián Olalla, Hospital Costa del Sol, Spain.

P009

Two cases of NNRTI resistance developed through planned interruption to long-acting injectable (LAI) Cabotegravir/Rilpivirine to facilitate conception

Dr Harry Coleman, Guy's and St. Thomas' NHS Foundation Trust, UK

P010

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study

Dr Andrew Ustianowski, North Manchester General Hospital, UK

P011

B/F/TAF five-year outcomes in treatment-naïve adults

Prof Anton Pozniak, Chelsea and Westminster Hospital, UK

P012

Real life experience of Doravirine in a large multi-centre HIV service

Dr Philip Saleh, Manchester University NHS Foundation Trust, UK

P013

Real world data of people living with HIV-2: experience of 7 London clinics

Stephanie Tyler, Guy's and St Thomas's NHS Foundation Trust, UK

P014

Real world data of doravirine usage: efficacy and safety outcomes in a large urban HIV service.

Stephanie Tyler, Guy's and St Thomas's NHS Foundation Trust, UK

P015

The safety and efficacy of the use of Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) with boosted Darunavir in clinical practice.

Stephanie Tyler, Guy's and St Thomas's NHS Foundation Trust, UK

P016

Antiretroviral regimen simplification for individuals receiving maraviroc

Dr Cristina Fernandez, North Manchester General Hospital, UK

P017

Impact of treatment adherence on efficacy of dolutegravir + lamivudine and dolutegravir + tenofovir disoproxil fumarate/emtricitabine: pooled week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies

Dr Eva Fernvik, ViiV Healthcare, Sweden.

P018

Three versus four drug regimens for people with high and very high viral loads

Dr Erica R M Pool, UCL, UK

P019

Dolutegravir/Lamivudine efficacy outcomes in people living with HIV with or without resistance results: 48-week pooled analysis

Dr Stefan Scholten, Praxis Hohenstaufenring, Germany.

P021

Multi-tablet, single-tablet, or long-acting antiretroviral treatment for HIV: a cross sectional study examining patient preference in two outpatient settings in the United States and Spain
Dr Ana Milinkovic, Chelsea and Westminster Hospital, UK

P022

Anti-retroviral therapy modification in an acute setting
Julia Bilinska, Guy's & St. Thomas' NHS Foundation Trust, UK

P023

Effectiveness and tolerability of the 2-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice
Dr Emilio Letang, ViiV Healthcare, Spain

P024

Treatment-emergent resistance to bictegravir with minimal risk factors
Dr Nadia Ahmed, Central North West London NHS Trust, UK

THEMED POSTER

TP06

What would people living with HIV do if faced with the poorly worded patient information leaflet for Paxlovid (nirmatrelvir /ritonavir) a new treatment for COVID-19 infection?
Dr Howell Jones, UCL, UK

BASIC SCIENCE: IMMUNOLOGY, VIROLOGY & PATHOGENESIS

P025

Evolution of Natural Killer (NK) cell responses during acute HIV-1 infection with distinct viral subtypes
Ms Aljawharah Alrubayyi^{1,2}
¹University of Oxford, Oxford, UK.

P026

People living with HIV have higher frequencies of circulating endothelial colony-forming cells: steps towards patient-specific models to evaluate cardiovascular risk
Dr Akif Khawaja, Imperial College London, UK

P027

Towards a prophylactic HIV vaccine: fine needle aspiration reveals cellular features of human lymph nodes compared with blood in the EAVI2020_01 study
Dr Katrina Pollock, Imperial College London, UK

P028

Effective CD4 count restoration linked to SARS-CoV-2 seroconversion following BNT162b2 mRNA SARS-CoV-2 vaccine in people living with HIV (PLWH) – a case report.
Dr Claire Mullender, University College London, UK

BEHAVIOUR, TRANSMISSION AND PREVENTION

P029

Increasing HPV vaccination uptake in PLWHIV: the need to improve both clinician training and patient health promotion
Mr Colin Fitzpatrick, University Hospitals Sussex, UK

P030

Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial
Dr Iain Reeves, Homerton hospitals NHS trust, UK

P031

'Health tourism' in the UK: challenging negative beliefs affecting the healthcare rights of migrants living with HIV
Dr Juan Anzola, National AIDS Trust, UK

P032

Terrence Higgins Trust and NHS Greater Glasgow & Clyde HIV testing campaign
Richard Angell, Terrence Higgins Trust, UK

P033

Optimising PrEP delivery - where and how people want to get PrEP. Findings from the 2020 PrEP User Survey
Amber Newbigging-Lister, UK Health Security Agency, UK

P034

Outcomes of a national complex HIV pre-exposure prophylaxis (PrEP) multi-disciplinary meeting
Dr Alice Taylor, Chelsea and Westminster NHS Trust, UK

P035

Barriers of PrEP use among people who recently acquired HIV: qualitative study. Findings from the SHARE (Surveillance of HIV Acquired Recently) initiative
Dr Adamma Aghaizu, UK Health Security Agency, UK

P036

Psycho-social factors affecting treatment compliance: The need for a patient-centred approach
Dr Isabelle Guest, North Bristol Trust, UK

Poster Abstracts

CHILDREN AND PREGNANCY

P037

An audit of management of HIV in pregnancy at an ISHS, compared to BHIVA Guidelines for the management of HIV in pregnancy and postpartum 2020

Dr Swarna Kumari Billakanti, Coventry and Warwickshire Partnership Trust, UK

P038

Use of video observed therapy as an adherence support for pregnant women living with HIV: A case report

Dr Luciana Rubinstein, Imperial College London, UK

P039

Confinement : Women, HIV And Pregnancy During The Covid-19 Pandemic In The UK

Ms Fungai Murau, 4M Mentor Mothers Network CIC, UK

P040

Exploring how women and birthing parents living with HIV make decisions about infant-feeding in the UK

Bakita Kasadha, University of Oxford, UK

P041

Trends in maternal characteristics and pregnancy outcomes among women living with HIV in the UK: 2014-19

Helen Peters, Integrated Screening Outcomes Surveillance Service, UCL, UK

P042

Pregnancy outcomes of women conceiving on ART at a London HIV clinic 2015-2020

Tay Rockett, St George's University Hospital, UK

CO-MORBIDITIES, CO-INFECTIONS AND HIV/ART COMPLICATIONS

P044

Cervical screening and HPV testing in young women living with perinatally acquired HIV: An interim assessment of the SHiP study

Dr Tamara Elliot, Imperial College London, London, UK

P045

Lipid disorders in HIV patients and impact on raised HDL cholesterol level

Swarna Kumari Billakanti, Coventry and Warwickshire partnership NHS trust, UK

P046

Prognostic relevance of lymphocyte-CRP-ratio and CRP-albumin-ratio as markers of inflammation in hospitalised adults with HIV

Dr Louisa Chenciner, Royal Free London NHS Foundation Trust, UK

P047

Assessing health-related quality of life in people with HIV and cognitive issues

Katie Alford, Brighton and Sussex Medical School, UK

P048

Inflammatory conditions necessitating immunosuppression in a cohort of young adults with perinatally acquired HIV: A case series

Dr Merle Henderson, Imperial College London, UK

P049

Impact of antiretroviral (ARV) and sleep hygiene intervention on sleep disturbance in people living with HIV(PLWH)

Dr Benjamin Goorney, Bolton Foundation Trust, UK

P050

Metabolic health of young adults with perinatally acquired HIV – an unknown need?

Dr Harry Coleman, Guy's and St. Thomas' NHS Foundation Trust, UK

P051

Spotlight on British South Asians living with HIV

Hasan Mohammed, Chelsea and Westminster Hospital NHS Trust, UK

P052

Smoking prevalence in people living with HIV in Cheshire and Merseyside is high, and supporting quitting could eradicate lifelong harms for over one quarter of the cohort

Dr Emily Clarke, Liverpool University Hospitals NHS Foundation Trust

P053

Impact on inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in treatment-experienced people with HIV-1: a systematic literature review

Dr Myooran Sithamparanathan, ViiV Healthcare, UK

P054

Patient-reported outcomes after switching to a 2-drug regimen of fixed-dose combination dolutegravir/lamivudine: 48-week results from the SALSA study

Lee A. Eviitt, ViiV Healthcare, UK

P055

Weight change in youth on tenofovir alafenamide (TAF)

Demiana Sidhom, Imperial College Healthcare NHS Trust, London, UK

P056

Associations between inflammatory profiles and cardiovascular disease risk among people living with HIV

Luxsena Sukumaran, University College London, UK

P057

The assessment of hepatic fibrosis and steatosis using transient elastography in youth with perinatal HIV

Dr Caroline Foster, Imperial College London, UK

P058

SARS-CoV2 vaccination acceptance in people with HIV

Dr Tristan Barber, Royal Free London NHS Foundation Trust, UK

P059

Hyper-eosinophilic syndrome with neurological and gastrointestinal involvement in a patient living with HIV

Dr Claire Pritchard, Manchester University Foundation Trust, UK

P060

Re-evaluation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): a feasibility study in women living with HIV in the UK

Dr Paola Cicconi, University of Oxford, UK

P061

Physical inactivity and associated health factors among patients attending an urban UK HIV and sexual health clinic: a secondary analysis of a clinic-based cross-sectional survey

Connor McAlpine, University College London, UK

P062

SARS-CoV-2 antibody seroprevalence in a large HIV clinic cohort

Dr Venkateswaran Sivaraj, Guy's and St Thomas' NHS Foundation Trust, UK

P063

Management of active tuberculosis in people living with HIV in a tertiary centre

Dr Tristan Banks, Manchester Foundation Trust, UK

P064

COVID infection and vaccination in a semi-rural HIV cohort

Dr Sophie Herbert, Northamptonshire Healthcare NHS Foundation Trust, UK

P065

Unexpected HIV Viral load rises in a COVID pandemic

Dr Sophie Herbert, Northamptonshire Healthcare NHS Foundation Trust, UK

THEMED POSTERS

TP02

Beliefs associated with COVID-19 vaccine uptake among people of Black ethnicities living with HIV: The Necessity Concerns Framework

Dr Shema Tariq, UCL, UK

TP05

Serological responses to SARS-CoV2 vaccination in people with HIV: The SCAPE-HIV Study

Dr Tristan Barber, Royal Free London NHS Foundation Trust, London, UK

TP07

Has the omission of routine blood monitoring of stable patients living with HIV (PLWH) during COVID adversely affected their health?

Ms Eleanor Swift, Brighton and Sussex Medical School, UK

Poster Abstracts

HIV TESTING, EPIDEMIOLOGY AND SURVEILLANCE

P066

Missed opportunities for diagnosing HIV in primary care

Dr Grace Bottoni, One Health Lewisham, UK

P067

Offering mass HIV blood testing to Primary Care patients via (MJog) Text Message: What we learnt and did it work?

Dr Grace Bottoni, South Lewisham Group Practice, UK.

P068

Introducing routine HIV testing to a gastroenterology ward: a junior doctor-led project

Dr Kevin Kuriakose, Manchester University NHS Foundation Trust, UK

P069

A re-audit of late diagnosed HIV positive individuals in 2016 and 2019 in Greater Manchester

Dr Emily Boardman, The Northern Contraception, Sexual Health and HIV Service, UK

P070

Improving testing for HIV in patients with community acquired pneumonia in Bradford Teaching Hospitals

Dr Vigneswaran Kandasamy, Bradford Teaching Hospitals, UK

P071

The use of routine diagnostic sequencing data to determine the molecular epidemiology and transmission dynamics of HIV-1 in Newcastle-upon-Tyne

Lisa King, Newcastle University, UK

P072

Improving blood-borne pathogen (BBP) testing on an adult inpatient mental health ward

Dr Amelia Cussans, Central and North West London NHS Foundation Trust, UK

P073

Measuring progress towards ending HIV transmission in England in the COVID-19 pandemic era

Dr Alison Brown, UK Health Security Agency, UK

P074

Characterising late presentation amongst people living with HIV in England who were previously diagnosed abroad

Dr James Lester, UK Health Security Agency, UK

P075

A whole systems approach to improving HIV testing in UK General Practice

Dr Aseem Mishra, Bracondale Medical Centre, UK

P076

HIV Testing in Indicator Conditions: Knowledge and Confidence in Primary Care

Dr Andrew Kong, Burn Brae Medical Practice, UK

P077

Service evaluation of the current standard of care for elite controllers, viral controllers and long term non-progressors in an age of antiretroviral therapy (ART) for all

Joseph Whelan, School of Medicine, University of Leeds, UK

P078

Regimens and outcomes for people with HIV and known hepatitis B core antibody positivity

Alif Aziz, University College London Medical School, UK

P079

Networking for HIV/AIDS prevention: impact of social media promotion on widening access and uptake of HIV testing

Dr Alessandro Ceccarelli, Fast Track Cardiff & Vale, UK

THEMED POSTER

TP03

Impact of the COVID-19 pandemic on HIV consultations in England

Miss Ammi Shah, UKHSA, UK

PSYCHOSOCIAL ISSUES AND QUALITY OF LIFE

P080

Real-world patient experience of long-acting injectable antiretroviral therapy (LAI-ART): The voice of young adults with perinatally acquired HIV (YAPAH)

Dr Julia Bilinska, Guy's and St Thomas' NHS Foundation Trust, UK

P081

Screening positive for depression is associated with poor self-reported adherence to antiretroviral therapy among people living with HIV attending a sexual health and HIV clinic in the UK

Jose Luis Paredes Sosa, University College London, UK

P082

Life Really Changed: Challenging people's perceptions of what it's like to live with HIV.

Richard Angell, Terrence Higgins Trust, UK

P083

Developing a model of dating for young adult women living with HIV

Cleo Fabian, Royal Holloway, University of London, UK

P084

Wellbeing of Black African women over 50 living with HIV

Rebecca Conway, Royal Holloway, University of London, UK

P085

Medicine-related burden in people living with HIV

Priya Sarma, The Universities of Kent and Greenwich, UK

P086

Stigma related to HIV pre-exposure prophylaxis use among men who have sex with men in Wales: a mixed methods study

Dr David Gillespie, Cardiff University, UK

P087

Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel

Dr Ana Milinkovic, Chelsea and Westminster Hospital, UK

P088

Ageing with HIV and co-morbidities: Exploring the social constructs of ageing and NCDs in the context of HIV in Zambia

Professor Jaime Vera, University Hospitals Sussex NHS trust, UK

P089

"The stigma being with HIV and double stigma being black": experiences and needs of racially minoritised people living with HIV.

Memory Sachikonye, Positively UK

P090

Understanding the perceived therapeutic need and value associated with novel long-acting antiretroviral regimens among people living with HIV in 12 European countries

Ama Appiah, ViiV Healthcare, UK

P091

"You are kind of left out there in a field on your own, and you have to figure it out yourself": responding to the needs of women ageing with HIV

Juddy Otti, Sophia Forum, UK

P092

Characteristics and outcomes of domestic abuse (DA) in people living with HIV (PLWH)

Dr Nadia Ahmed, Central North West London NHS Trust, UK

P093

A review of the management of people living with HIV in long-term residential/nursing care in a greater London cohort.

Dr Dawn Friday, London North West University Teaching Hospital, UK

P094

Improving U=U discussions with people living with HIV: an audit of practice in an infectious diseases clinic

Dr Todd Cooper, Manchester Foundation Trust, UK

THEMED POSTERS

TP08

Evaluating the mental health (MH) impact of omitting routine monitoring for stable patients with HIV during the COVID-19 pandemic

Mr George Upton, Brighton and Sussex Medical School, UK

Poster Abstracts

SERVICE DEVELOPMENT, EDUCATION & TRAINING

P099

Vaccine administration and monitoring in a regional HIV centre: a service evaluation

Georgia Jefford, University of Cambridge School of Clinical Medicine, UK

P100

Improving the quality of care for people living with HIV (PLWH) in Primary Care

Funke Adeniji, Crays Primary Care Network, UK

P101

HIV care during Covid: Learning from patients' experiences

Dr Iain Reeves, Homerton University Hospital NHS Foundation Trust, UK

P102

Reduced monitoring in a stable patient pathway: Patients' perspective and co-design.

Stephanie Tyler, Guy's & St. Thomas' NHS Foundation Trust, UK

P104

'Zero HIV': a primary care population-based project to increase HIV diagnosis and improve engagement of patients living with HIV

Dr Grace Bottoni, One Health Lewisham, UK

P105

A quality improvement project to increase the uptake of Human Papilloma Virus vaccine for HIV+ women aged <40

Dr Giulia Rinaldi, University College Hospital NHS Trust, UK

P106

Achieving high levels of engagement among UK primary and secondary healthcare professionals using a World AIDS Day digital media, augmented reality, and email education campaign

Neal Marshall, Gilead Sciences Ltd, UK

P107

Patient and clinician experience of video and telephone appointments (VATA) vs face-to-face appointments (FTFA) in a large urban HIV service.

Dr Sarah Keegan, Guys and St Thomas' NHS trust, UK

P108

The experiences of individuals living with HIV in Ireland attending for out-patient physiotherapy.

Dr Adam McDermott, St. James's Hospital, Ireland.

P109

A simulation modelling evaluating the impact of mobile health interventions on HIV/AIDS service delivery

Dr Shola Adeyemi, , Bohemian Smartlytics Ltd, UK

P110

Success of peer mentoring in supporting patients to improve virological control: a collaborative project

supported by the Fast Track Cities (FTC) initiative

Jaime Sylla, Metro, London, UK

P111

From engagement to co-production: London's Improvement Collaborative as a model for partnership between clinical and community-based services

Professor Jane Anderson, Homerton University Hospital NHS Trust, UK

P112

Intervention to support retention in care in individuals at risk of disengagement during the COVID 19 pandemic

Dr Dorcas Obeng, Manchester University Foundation Trust, UK

P114

General population understanding and self-reported attitudes towards people living with HIV.

Katie Short, Idsall School Sixth Form, UK

P115

Improving access to hepatitis C treatment in people living with HIV

Justine Mellor, Manchester University NHS Foundation Trust, UK

P116

Development of a multi-professional approach for holistic frailty assessments in the HIV population to improve patient care

Justine Mellor, Manchester University NHS Foundation Trust, UK

P117

Patient and staff perspective on screening for domestic abuse (DA) in people living with HIV (PLWH) during a COVID pandemic

Dr Nadia Ahmed, Central North West London NHS Trust, UK

P119

Quality improvement project: A review of patients with historic Didanosine (ddl) exposure to ensure assessment for liver toxicity

Dr Harry Coleman, Guy's and St.Thomas' NHS Foundation Trust, UK

P120

Identifying factors associated with low COVID-19 vaccination uptake in a diverse London HIV cohort

Dr Nur-Emel Noubani, Croydon University Hospital, UK

THEMED POSTER

TP04

The impact of deferred monitoring in people living with HIV during the COVID-19 pandemic

Miss Stephanie Tyler, Guy's and St Thomas's NHS Foundation Trust, UK

STI, REPRODUCTIVE HEALTH, CONTRACEPTION & SEXUAL DYSFUNCTION

P095

The prevalence and impact of severe hot flushes among women aged 45-60 living with HIV in England

Hajra Okhai, University College London, UK

P096

Interest in, and feasibility of, a genital Herpes Simplex Virus Type-2 infection vaccine study in a cohort of people living with HIV.

Elizabeth Greenfield, UCLMS, UK

P097

Implementing a menopausal service for women living with HIV (WLWH)

Dr Amy Mammen-Tobin, Leeds General Infirmary, UK

P098


Preferences for the management of sexually transmitted infections in the South African health system: A discrete choice experiment

Dr Collins Iwuji, University of Sussex, UK

Industry Satellite Symposia & Workshops

WEDNESDAY 20TH APRIL 2022

13:15 – 14:00 **Workshop**
sponsored by
Gilead Sciences



Title:
STOP, COLLABORATE AND LISTEN:
Supporting people to live their best
lives

Host: Pantii Bliss

Panellists:
Dr. Leena Sathia – Medical Director,
Gilead Sciences
Dr. Naomi Sutton – Sexual Health
Consultant, Rotherham
Dr. Rageshri Dhairyawan –
Consultant Physician in Sexual Health
and HIV Medicine, Barts Health
NHS Trust
Angelina Namiba - HIV advocate,
4M Network
Garry Brough – HIV advocate,
Positively UK

14:15 – 15:15 **Satellite Symposium**
sponsored by
ViiV Healthcare



Title:
Onwards and Upwards: Optimising
HIV treatment for People Living with
HIV Now

Chair:
Dr Laura Waters, Mortimer Market
Centre London

Speakers:
Dr Tristan Barber, Royal Free Hospital
London
Dr Claire Dewsnap, Sheffield
Teaching Hospitals NHS Foundation
Trust

THURSDAY 21ST APRIL 2022


08:00 – 08:45 **Satellite Symposium**
sponsored by
Janssen



Title:
The Future of Patient Centred Care

Chair:
Dr Ana Milinkovic, Chelsea &
Westminster Hospital NHS FT

Speakers:
Dr Ana Milinkovic, Chelsea &
Westminster Hospital NHS FT
Fernando Monteiro, Bloomsbury
HIV Clinic, Mortimer Market Centre,
Central and North West London
NHS FT
Dr Daniella Chilton, Guy's &
St Thomas' NHS FT
Linda Panton, Western General,
NHS Lothian
Dr Roberta Brum, Chelsea &
Westminster Hospital NHS FT
Professor Andy Ustianowski, North
Manchester General Hospital

14:15 – 15:15 **Satellite Symposium**  **GILEAD**
sponsored by
Gilead Sciences

Title:
Confidence Matters – What's
important in HIV care now and in the
future

Chair:
Dr Mark Lawton, Consultant in
Sexual Health & HIV and Clinical
Lead at the Liverpool Centre for
Sexual Health

Speakers:
Ms Nadia Naous, Lead Directorate
Pharmacist - HIV and GUM, Chelsea
and Westminster Hospital NHS
Foundation Trust
Professor Mark Nelson, Consultant
Physician at the Chelsea and
Westminster Hospital, London

FRIDAY 22ND APRIL 2022

11:15 – 12:15 **Satellite Symposium**  **MSD**
sponsored by
MSD

Title:

Doravirine's ▼use in clinical practice -
case based discussion

Chair:

Dr Steve Taylor, HIV Consultant,
University Hospital Birmingham

Speakers:

Professor Marta Boffito, HIV
Consultant, Chelsea and Westminster
Hospital

Dr Amanda Clarke, HIV & Sexual
Health Consultant, University
Hospitals Sussex NHS Foundation
Trust

13:15 – 14:00 **Workshop**
sponsored by
ViiV Healthcare



Title:

Long-Acting Injectables: A New
Choice for People Living with HIV

Chair:


Dr Emily Clarke, Royal Liverpool
University Hospital

Speakers:

Dr Sebastian Noe, MVZ München
am Goetheplatz, Munich, Germany

Patricia Anderson, Brownlee Centre,
NHS Greater Glasgow and Clyde

Speakers Biographies



Dr José Arribas, Head. Infectious Diseases Unit, La Paz University Hospital, Spain

Dr. José R Arribas is currently the head of the Infectious Diseases Unit and Research Director of HIV and Infectious Diseases at La Paz Hospital, professor of Medicine at Autonoma University School of Medicine Madrid and Research Director of HIV and Infectious Diseases at Hospital La Paz Institute for Health Research - IdiPAZ. Dr. Arribas received his medical degree from the Complutense University School of Medicine, Madrid. Following this, he completed his residency in Internal Medicine at La Paz Hospital before going on to pursue a fellowship in Infectious Diseases at Washington University, St. Louis, Missouri, USA. During his fellowship, he participated in clinical research at the Washington University AIDS Clinical Trials Unit. His research interests, which include antiretroviral therapy, development of new antiretrovirals and emerging infectious diseases have driven the publication of over 360 scientific papers as author, many of them clinical trials or antiretroviral therapy. Dr. Arribas is the current president of GESIDA (Spanish Group for the study of AIDS), former chair of the antiretroviral panel of the European AIDS Clinical Society (EACS) guidelines and member of the editorial committee of Antiviral Therapy, HIV Medicine, Open Forum in Infectious Diseases and Lancet HIV.



Mr Bertrand Audoin, Vice-President, International Association of Providers of AIDS Care (IAPAC)

Bertrand, MBA, CONM (Chevalier de l'Ordre National du Mérite), has been Vice-President of the International Association of Providers of AIDS Care (IAPAC) since 2014. He also teaches Human Rights at EDHEC Business School since 2008. Bertrand is a 1992 EDHEC- and a 2008 French Defense Institute alumni and has been working in the fight against HIV/ AIDS for 30 years, starting in New Zealand in 1992. He was CEO of French NGO and fundraiser Sidaction from 1996 to 2011, and ED of the International AIDS Society, from 2011 to 2014.



Dr Chitra Sharma Babu, Consultant Physician in Sexual Health and HIV Medicine, Manchester NHS Foundation Trust, UK

Dr Chitra Babu is a consultant in Sexual Health and HIV Medicine at the Hathersage Centre, Manchester Royal Infirmary. She is Clinical Lead for the Northern Contraception, Sexual Health and HIV Service which provides services across Manchester and Trafford regions. Her special interests include HIV & Reproductive Health and, HIV & Neurology. She is a strong advocate for equality of access to health services for all.



Dr Angela Bailey, Consultant in Sexual Health, Buckinghamshire Healthcare NHS Trust, UK

Angela Bailey is a Consultant in Sexual Health and HIV at Buckinghamshire Healthcare NHS Trust and has worked in HIV for over 15 years, including a year in Burma with MSF where she saw more opportunistic infections than 5 years in the UK. She previously worked in the HIV/TB service, the Family HIV clinic and in the inpatient HIV service at St Mary's hospital in London. She is an examiner for the Diploma of HIV Medicine and a member of the BHIVA guidelines subcommittee.



**Dr Laura Byrne, Consultant in HIV Medicine,
St George's University Hospitals NHS Foundation Trust, UK**

Laura is a consultant in HIV medicine at St George's University Hospitals NHS Foundation Trust. She has a special interest in managing HIV in pregnancy, having completed a PhD in this field at the UCL GOSH Institute of Child Health, and is currently vice-chair of the BHIVA HIV & pregnancy guidelines writing group. Laura is also admissions tutor for Medicine and honorary senior lecturer at St George's, University of London.



Dr Daniella Chilton, HIV Consultant, Guy's and St Thomas' NHS Trust, UK

Dr Daniella Chilton is a HIV consultant at Guys and St Thomas' (GSTT) since 2009, specialising in young adults with HIV, comorbidity and inpatients. She leads the 'Living well clinic' for people living with HIV and comorbidity and has a deep interest in personalised care, patient activation and lifestyle medicine. She became HIV clinical lead in 2021. At trust level, Daniella has a role in transformation, and is clinical lead for the patient initiated follow up (PIFU) programme at GSTT.



Rob Cookson, Deputy Chief Executive, LGBT Foundation, England

Rob has over 20 years' experience of working in the Voluntary & Community Sector. His current role is Deputy Chief Executive of LGBT Foundation, a Charity which supports LGBTQ+ Communities. As the LGBT Foundation's Strategic lead for Sexual Health, Rob has been involved in a range of sexual health initiatives, both locally and nationally. Rob is passionate about getting to zero new HIV infections and zero stigma. As one of the Co-Chairs of Greater Manchester's Fast Track Cities, he has the pleasure of working with a range of communities and wider stakeholders in striving to make this a reality. Key passions include equality and working with communities to create improved health outcomes for LGBTQ+ people. In his spare time, Rob enjoys trips in his Campervan (called Brenda!) with his husband Richard and Jack Russell Ruby.



Dr Sara Croxford, Principal Scientist, UK Health Security Agency, UK

Sara Croxford is a Principal HIV/STI Prevention and Surveillance Scientist at the UK Health Security Agency. She completed her PhD in Epidemiology and Public Health at the University College London in 2020. With over ten years of experience in public health and HIV, Sara's research interests include monitoring the quality of care and outcomes among people with HIV and blood-borne virus prevention among people who inject drugs.



Dr Hilary Curtis, Clinical Audit Co-ordinator, BHIVA, UK

Hilary Curtis trained as a scientist before joining the British Medical Association in the mid-1980s as a public health policy researcher. She became executive director of the BMA Foundation for AIDS (later Medfash), specialising in HIV education for professional groups and policy makers, before going freelance around the turn of the millennium. Co-ordinating BHIVA's clinical audit programme has been a mainstay of her work since then. The 2022 national audit will be her last project for BHIVA before retirement.



Professor Stéphane De Wit, Head, Infectious Diseases, Saint-Pierre University Hospital, Belgium

Stéphane De Wit is Chief of the Department of Infectious Diseases at the Saint-Pierre University Hospital in Brussels. He is Professor of Infectious Diseases at the Free University of Brussels. As a clinician and clinical researcher, Stéphane De Wit has been active in the field of HIV/AIDS since 1983. He is author or co-author of more than 300 articles and more than 430 communications at conferences. He is coordinator of the Brussels Saint Pierre Cohort, Chair of the Belgian HIV Research Consortium BREACH, Founding member and co-chair of the European NEAT-ID Foundation. He was previously Chair of the COHERE Executive Committee and secretary of the Governing Board of the European AIDS Clinical Society (EACS). He has been Chair of the "8ème Conférence Internationale Francophone HIV/Hépatites" (AFRAVIH Brussels 2016).



Dr Caroline Foster, Consultant in Adolescent Infectious Diseases, Imperial College Healthcare NHS Trust, UK

Dr Caroline Foster is a Consultant in Adolescent Infectious Diseases at Imperial College Healthcare NHS Trust and is the clinical lead for transitional care in HIV. Her research interests include the long term outcomes for adults born with HIV.



Jim Fielder, Head of Living Well, Terrence Higgins Trust, UK

Jim has been Head of Living Well at Terrence Higgins Trust since 2018, where he has been developing a range of wellbeing, peer led and therapeutic services for people living with HIV across the UK. Prior to this he set up and ran a programme supporting gay and bisexual men living with HIV at Positively UK. Before working in the HIV sector, he worked in a variety of charity and public sector roles developing household waste recycling programmes and public waste awareness campaigns. Jim has been living with HIV himself for seven years.



Professor Anna Maria Geretti, Professor of Virology & Infectious Diseases, University of Rome Tor Vergata, Rome, Italy and King's College London, London, UK

Professor Anna Maria Geretti – MD, PhD, FRCPath – is an academic clinician who specialises in virology. She is based in Italy and the United Kingdom and is affiliated with the Dept. of Infectious Diseases of the University of Rome Tor Vergata, has a visiting professorship with the Dept. of Infectious Diseases of King's College London, and holds the role of head of virology early development with Roche Pharma Research & Early Development. Her research, primarily for translation of science into clinical care applications, has led to over 250 publications (h-index 60) and it spans laboratory-based, patient-side, and epidemiology projects, including drug and biomarker development, field work in sub-Saharan Africa, and collaborations with the World Health Organization. Anna Maria is Editor in Chief of the BMJ journal Sexually Transmitted Infections. Her ambition is to deliver an impact that promotes progress of medicine and science and is globally beneficial to patient care.



Professor Yvonne Gilleece, Honorary Clinical Professor and Consultant in HIV Medicine, Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust

Professor Yvonne Gilleece trained in Dublin and London, and is Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health at Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust. She is a national and international leader on HIV in Women and is mediate past Chair of the BHIVA Pregnancy Guidelines, Chair of WAVE, Chair of SWIFT, promoting research in women living with HIV. She is currently the Honorary Secretary of BHIVA. She also specialises in HIV and Bone and HIV and Hepatitis Coinfection & Liver Dysfunction.



Anne Glew, HIV Prevention Coordinator, The Brunswick Centre, England

Anne Glew is the HIV Prevention Coordinator within the HIV Service at the Brunswick Centre, a small charitable organisation that works across two local authority areas in West Yorkshire made up of small urban and remote rural areas. She works with communities most at risk of HIV to inform, empower and support individuals from these communities to prevent HIV transmission, and seeks to redress the health and social inequalities experienced by these communities. Her background is in Community development, she managed a Local Authority Community Work Team for over 25 years and puts her experience to good use in this role. Using community development models to encourage individuals to be actively involved in the identification and definition of the needs of their own communities. Anne represents the Brunswick Centre at HPE where they are a Local Activation Partner (LAP).



Anthony Harrison-West, Sexual Health Manager, Renaissance UK

Anthony joined Renaissance UK, a substance misuse and sexual health charity in Lancashire, as a Sexual Health Outreach Worker in 2014. In 2015 he was successful in moving into the role of LGBTQ+ Community Development Lead for the HORIZON project, which is Blackpool's integrated substance misuse and non-clinical sexual health service. Whilst in this role Anthony lead on all HPE activity delivered by Renaissance UK and in 2018 was promoted to Sexual Health Manager for the service. Anthony now manages all sexual health activity for Renaissance UK which includes the HIV Support services delivered in Blackpool, Lancashire, and Blackburn with Darwen and our PSE sexual health outreach service, as well as continuing to lead on Renaissance UK's Local activation partner activity for HIV Prevention England. Renaissance UK proudly work alongside the local clinical services delivered by Blackpool Teaching Hospitals NHS Trust in Lancashire and Blackpool & Brook in Blackburn with Darwen. An example of this partnership working is the launch of the M2M clinic in 2018. Based at 102 Dickson Road in Blackpool, M2M offers out of hours asymptomatic sexual health screening to anyone identifying as male. All social media platforms @RenaissanceDLL



Dr Caroline Johnson, Clinical Psychologist, Imperial College Healthcare Trust, UK

Caroline Johnson PhD CPsychol, is a Clinical Psychologist with more than 15 years experience working in hospital settings in the NHS and Australian public healthcare services. She has an interest in the impact of early life experience on long term mental health and how this affects engagement in health care settings. She is currently employed as Deputy Lead for the Psycho-oncology service at Imperial College Healthcare Trust, having previously worked across oncology, haematology, sickle cell, sexual health, stroke and neuropsychology services.



Dr Howell Jones, Academic Clinical Fellow and Specialist Registrar in Geriatric and General Internal Medicine and Clinical Fellow in HIV Medicine, MRC Unit for Lifelong Health and Ageing, UCL, Royal Free Hospital, Royal Free London NHS Foundation Trust, and Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK

Dr Jones is currently dual training in Geriatric and Internal Medicine in London, United Kingdom and is a former NIHR academic clinical fellow. He currently works at both the Mortimer Market Centre and the Royal Free Hospital with his academic attachment being with the MRC Unit for Lifelong Health and Ageing at UCL. His specialist interest is ageing in people living with HIV and his research interests are focused on the impact of multimorbidity and frailty in older people living with HIV, delivery of holistic health care to this group and increasing awareness and knowledge of people living with HIV and older LGBTQ+ people amongst those working in Geriatric Medicine. Clinically he helps deliver general HIV care at Mortimer Market as well as delivering the Sage clinic at the Royal Free Hospital which is specifically aimed at older people.



Dr Harriet Kemp, NIHR Clinical Lecturer, Imperial College Healthcare NHS Trust, UK

Dr Kemp is an NIHR Clinical Lecturer with APMIC & the Pain Research Group. Clinically she works as an anaesthetic registrar in the Imperial School of Anaesthesia. Having completed an NIHR Academic Clinical Fellowship in Anaesthetics, Dr Kemp was appointed to the NeuroPain Grant to investigate pain in patients with HIV. She completed her doctoral thesis on chronic pain in HIV infection in 2019. Her areas of interest include quantitative sensory testing, conditioned pain modulation, and other deep phenotyping measures in neuropathic pain. She was also the joint project lead for the Pain in INTensive Care (PAINIT) Study with Dr Helen Laycock and the Pan London Perioperative Audit and Research Network and continues to work on studies investigating acute and chronic pain in the critically ill. She is also currently working on the NIPPR study (funded by the British Pain Society Clulow Award) investigating neuropathic pain in HTLV-1 infection with the National Centre for Human Retrovirology.



Professor Sebastian Lucas, Emeritus professor of pathology, Guy's & St Thomas' NHS Foundation Trust, UK

Professor Lucas has been studying HIV disease – both in biopsy and morbid anatomy – for more than 40 years. And has practiced pathology for 48 years. In that time, he has witnessed, and contributed somewhat to, the changing patterns of death management, investigation and certification. As HIV disease changes with improvements in clinical treatment and infected people live longer, it is ever more important that we categorize their deaths optimally. The current minimal – and the ideal – requirements of death certification in the UK will be discussed.



Dr Swapna Mandal, Consultant Respiratory Physician, Royal Free London NHS Foundation Trust, UK

Dr Mandal is the lead Consultant Physician in Sleep and Ventilation at the Royal Free London NHS Foundation Trust, focusing on the management of sleep disordered breathing, the service covers a large geographical area treating range of patients with often complex needs including those with progressive neurological disorders and ventilatory failure. Additionally, she has set up a joint respiratory and palliative advanced respiratory care clinic for patients with chronic respiratory conditions requiring input from both specialties. She is also the clinical lead for lung function services across the trust and has introduced innovative diagnostic pathways. She continues her pursuit of academic interests in sleep and ventilation medicine and is supervising several PhD students as well as actively improving patient care through quality improvement projects. She won a BMJ award for an innovative outpatient pathway and was a regional finalist for the Peter-Carr Award. More recently she has led the post-acute COVID service at the Royal Free Hospital and has also published in this area.



Fiona Marra, Lead Pharmacist HIV/HCV FRPharmS (Consultant), NHS Greater Glasgow and Clyde, and University of Liverpool, UK

Fiona Marra works clinically in Glasgow where she is Lead Clinician for Paediatric Infection and Immunology Network for Scotland, and senior clinical pharmacist for adult HIV/HCV. She is also Principal Pharmacist and part of the Editorial Board of the University of Liverpool, Drug Interactions websites, where she writes the content. Fiona is completing a PhD in Clinical Pharmacology of HCV and has completed diplomas in International development and travel medicine and MSc in Advanced Pharmacy. She sits on the Committees of the British HIV Association (BHIVA) Hepatitis Group, the Scottish Malaria Group and is part of the Editorial board of Scottish paediatric Infection and Immunology network (SPAIIIN). She is an author of the EASL Recommendations for HCV 2018 and 2020 and lectures globally on HIV and HCV drug interactions. She has published substantially in this field.



Dr Louise Melvin, Consultant in Sexual & Reproductive Health, Sandyford Sexual Health Service, UK

Louise Melvin is a Consultant in Sexual & Reproductive Health (SRH) based in Glasgow at Sandyford Sexual Health Service. Louise first qualified as a pharmacist, switching soon after to medical training. After specialty training in the east of Scotland in general Obstetrics & Gynaecology, followed by subspecialty training in SRH, Louise moved back to the west in 2008, taking up a consultant post at Sandyford. She was the Director of the Faculty of SRH (FSRH) Clinical Effectiveness Unit until 2014. Having acquired a cohort of transgender patients with SRH issues, Louise was invited to join the NHS Greater Glasgow & Clyde gender service which is hosted by Sandyford. The service takes referrals from all children and adolescents under 18 years in Scotland, and adults from six of the Scottish health boards. There is no formal training programme for transgender healthcare. Gender incongruence is now classed as a condition related to sexual health, although psychological comorbidity is common. Therefore, the multidisciplinary team members in the Glasgow gender service come from a variety of healthcare backgrounds. Louise is currently interim clinical lead for the gender service in addition to her SRH work.



Ms Fungai Murau, Independent Consultant, UK

Fungai Murau is a researcher in the HIV field with special interest in mental health (quality of life for people living with HIV), migration and educating adolescent girls in making informed choices about their sexuality and wellbeing. Fungai studied at the renowned Institute of Development studies with her MA (poverty and development) dissertation focusing on the mental health of undocumented women living with HIV in the UK. Fungai currently works as an independent consultant focusing on policy, advocacy and project delivery. Fungai is affiliated with national and international advisory boards. These include, board member at Beyond Stigma, SWIFT (Supporting Women with HIV Information Network), and a member of the Organising Committee of the annual International Women and HIV Workshop.



Hajra Okhai, Research Statistician, University College London, UK

Hajra is a Research Statistician based at the Institute for Global Health, University College London since 2018. She has collaborated on designing, analysing and publishing a range of research projects exploring clinical and psychological outcomes using large, representative datasets of people living with HIV in the UK including the UK Collaborate HIV Cohort (CHIC), Positive tRansitions through Menopause (PRIME) and Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) studies. Currently, Hajra is collaborating with SWIFT (Supporting Women with HIV Information Network) to understand the knowledge of health care providers and the barriers and facilitators they face in relation to the diagnosis and treatment of low bone mineral density (BMD) amongst women living with HIV.



**Professor Chloe Orkin, Professor of HIV Medicine,
Queen Mary University of London, UK**

Chloe Orkin is Professor of HIV Medicine at Queen Mary University of London and Consultant Physician at Barts Health NHS Trust where she leads on clinical trials in HIV. She is the Academic Lead for Equality Diversity and Inclusion for her medical school and Director for the SHARE research centre for health equity. Chloe is immediate past Chair of the British HIV Association, President of the Medical Women's Federation and a member of the governing council for the International AIDS Society. Her specialist interests are anti-retroviral therapy and health equity.



Dr Roger Paredes, Head, infectious Diseases Department, Hospital Germans Trias i Pujol, Catalonia, Spain

Roger Paredes, MD, PhD, is the Head of the Infectious Diseases Department, Germans Trias i Pujol Hospital and Head of the Microbial genomics Group @ irsiCaixa, both in Badalona, Catalonia, Spain. He obtained a PhD in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialised in HIV resistance, at Brigham & Women's Hospital in Boston and Harvard Medical School, thanks to a post-doctoral scholarship from "la Caixa". He has demonstrated the clinical utility of new methods of sequencing HIV in both high- and low-income countries. He is a member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee and of the International Antiviral Society-USA, which publishes an international annual update of drug resistance mutations in HIV-1. His group has led pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. He is Coordinating of the Horizon 2020 10M-euro MISTRAL Project to decipher the role of the microbiome on HIV pathogenesis and cure (www.mistral-hiv.eu)



**Dr Dimitra Peppas, Associate Professor in HIV Immunology/Honorary
Consultant in HIV Medicine,
University College London, UK**

Dimitra Peppas is an Associate Professor in HIV Immunology and Honorary HIV Consultant at the Institute of Immunity and Transplantation (IIT), UCL. She runs an immunology research lab studying immunity in human disease including chronic viral infections with HIV, HBV and emerging viral infections (SARS-CoV-2). Her lab has expertise in adaptive immunity and NK cell biology with a focus on translational research and the identification of new targets for 'cure' strategies and vaccine development. Other projects focus on dissecting the network of drivers of chronic inflammation associated with premature ageing and multi-morbidity in people living with HIV.



**Professor Matt Phillips, Consultant GUM & HIV/ Honorary Professor, North Cumbria
Integrated Care NHS FT/
University of Central Lancashire, UK**

Matt is a consultant in GUM & HIV in Cumbria, having trained in Greater Manchester and Dublin. He has a longstanding interest in ethics and the law as applied to HIV and GUM and has been involved in a number of publications relating to these subjects. Matt recently chaired the writing group for the update of the BHIVA position statement on HIV and the Law, chairs his trust's ethics committee, and sits on the BMJ Ethics committee. He is honorary professor at the University of Central Lancashire.



Dr Erica Pool, Registrar / Academic Clinical Fellow, Mortimer Market Centre / University College London, UK

Dr Erica Pool is an ST4 Specialist Registrar in Genito-Urinary Medicine at Mortimer Market Centre, London. She is an NIHR Academic Clinical Fellow at UCL. Erica trained in medicine in Leeds and completed a Masters in Public Health at LSHTM. She has held clinical academic posts in York, Brighton, and London and has experience working on a wide range of HIV, PrEP, and STI research including large phase III and IV clinical trials, implementation studies, and observational studies. She has been on the writing committee for the BHIVA opportunistic infections guidelines and BHIVA BASHH PrEP Guidelines. Erica was a member of the BHIVA External Relations Committee (2017-2020) and is a STASHH mentor.



Professor. Dr Jürgen Rockstroh, Head of Infectious Diseases, University Hospital Bonn, Germany

Jürgen Rockstroh, MD, is Professor of Medicine and Head of Infectious Diseases at the University Hospital of Bonn in Germany. He earned a Doctor of Medicine degree from the Rheinische Friedrich-Wilhelms University of Bonn, and completed his residency in the Department of Medicine also at the University of Bonn. In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. More recently, he has also started working on the impact of COVID-19 on HIV-coinfection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV, hepatitis co-infection and COVID-19. From 2007-2011 he was elected as the president of the German AIDS Society. He is also since 2009 a member of the executive committee of the European AIDS Clinical Society (EACS) and from 2011-2020 member of the governing council of the International AIDS Society. He also was the chair of the National German AIDS Advisory Panel from 2011-2017 and the EACS coinfection guidelines from 2008-2017. In 2015 Professor Rockstroh was elected chair of HIV in Europe (in 2019 renamed as EuroTEST) and from 2019-2020 president for EACS. The German Society for Infectious Diseases awarded Dr Rockstroh and his co-authors the prize in clinical infectious diseases in 2002, and the national AIDS research prize in 2005. Dr Rockstroh has authored or co-authored over 700 publications in peer-reviewed journals, and over 100 book chapters.



Professor Caroline Sabin, Professor of Medical Statistics and Epidemiology, University College London, UK

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is the Director of the NIHR Health Protection Research Unit in Blood-Borne and Sexually Transmitted Infections at UCL. She is also the current vice-chair of the British HIV Association (BHIVA). Caroline's interests are in describing the natural history of HIV infection, identifying prognostic markers and describing responses and adverse events to cART. She established the UK Collaborative HIV Cohort (UK CHIC) Study, was the principal statistician and co-lead for the D:A:D Study and is the co-principal investigator for the POPPY study, a large cohort set up to investigate the associations of ageing and HIV in the UK and Ireland. Since the start of 2020, she has been one of the two Editors-in-Chief of HIV Medicine, BHIVA's flagship journal.



Dr Whitney Scott, Lecturer in Clinical Health Psychology/Clinical Psychologist, King's College London/Guy's & St Thomas' NHS Foundation Trust

Dr Whitney Scott is a Lecturer in Clinical Health Psychology in the Health Psychology Section of the Institute of Psychiatry, Psychology & Neuroscience at King's College London. She is also a registered Clinical Psychologist and the Research Lead at the INPUT Pain Management Unit at Guy's and St Thomas' NHS Foundation Trust in London, UK. She has published nearly 70 peer-reviewed journal articles on psychosocial factors related to pain and psychological treatments for managing persistent pain, including among people living with HIV. Her work has been funded by the International Association for the Study of Pain and the National Institute for Health Research.



Mr Alex Sparrowhawk, Partnerships Coordinator, Terrence Higgins Trust, UK

At Terrence Higgins Trust, Alex leads on HIV Prevention England's work to build strategic partnerships across the health system and with key stakeholders, and supports capacity and skills development within the HIV and sexual health sector. Alex also Chairs the UK Community Advisory Board (UK-CAB, the HIV Treatment Advocates Network). Alex is passionate about developing meaningful partnerships with key stakeholder groups across the sector, including people living with and affected by HIV.



Grant Sugden, Chief Executive, Waverley Care, UK

Grant Sugden is Chief Executive of Waverley Care, Scotland's HIV and Hepatitis C charity which provides prevention and support services across Scotland. Grant graduated in Economics and Politics from the University of Edinburgh and then qualified as a social worker, working in child protection for a number of years. He joined Waverley Care in 2011 and since then has led the organisation to grow its work across Scotland.



Dr Shema Tariq, Clinical Academic/Consultant HIV Physician, University College London/Mortimer Market Centre, UK

Shema Tariq has been a Clinical Academic at UCL's Institute for Global Health and a consultant HIV Physician at Mortimer Market Centre since 2015 (where she has developed and leads a specialist HIV and menopause service). Her academic interests are in HIV and digital health, HIV seroconversion, and HIV in women across the life course. Previous experience includes MRC-funded doctoral research into HIV care in pregnancy, and a Fulbright Scholarship to the HIV Center in New York. She is Chief Investigator of the PRIME Study, an NIHR-funded study on HIV and menopause which has informed both national and European guidelines. Shema is co-investigator on CASCADE (European-wide study of HIV seroconversion), INTUIT (investigating use of patient-generated data in HIV), NOURISH-UK (a study of HIV infant-feeding decision-making), and COV-Africa (exploring COVID-19 in the GEN-Africa cohort). She is also part of the GROWS project, a collaboration with three HIV charities to develop peer-support for women ageing with HIV. She is Chair of the BASHH Lay Research Panel, Trustee of Positively UK and Tommy's Baby Charity, and past Vice-Chair of the BHIVA Pregnancy Guidelines committee.



**Dr Maya Tickell-Painter, ST5 Infectious diseases/medical microbiology,
Manchester Foundation Trust, UK**

Maya is a specialist registrar, currently training in infectious diseases and microbiology in Manchester. She studied her Diploma in Tropical Medicine and Hygiene (DTM&H) at the Liverpool School of Tropical Medicine (LSTM) in 2015. Subsequently she worked for the Cochrane Infectious Disease Group and was the first author of two systematic reviews on mefloquine when used as chemoprophylaxis for malaria. Maya enjoys teaching and has completed a Professional Certificate in Supporting Learning (SEDA). She has taught on TB control and evidence synthesis on the DTM&H and the Diploma of Tropical Nursing at LSTM. She works with the local charity MedAct Manchester and has conducted research with this group on healthcare access for asylum seekers and refugees in England. Maya was on the HIV-2 guidelines writing group which has recently released the updated BHIVA guidelines for the management of HIV-2 2021.



**Dr Athavan Umaipalan, HIV/GUM Consultant,
Barking, Havering & Redbridge NHS Trust, UK**

Dr Umaipalan has been a consultant in North East London for 5 years and is the HIV lead Consultant for BHR Trust based at Barking Hospital. He has a special interest in HIV testing and prevention. He is the principal investigator for HIV and sexual health studies at the Barking, Havering & Redbridge NHS Trust.



**Dr Alison Uriel, Specialty doctor in Infectious Diseases,
Manchester University Foundation Trust, UK**

Dr Alison Uriel joined the Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital in 2009, on return from New York where she had been working in the research department of the Division of Liver Diseases, Mount Sinai Hospital. She has been Principal and Sub Investigator for numerous clinical trials evaluating new treatments for HIV, Hepatitis B and C, Clostridium difficile and atypical mycobacteria. Since the start of the COVID pandemic, she has been involved with the planning and delivery of COVID vaccine and long-acting monoclonal antibody trials, and COVID-19 treatments including anti-viral and immunomodulatory drugs. She was appointed NIHR Clinical Research Network Greater Manchester clinical lead for infectious diseases in July 2020 and is currently Research Lead for the Infectious Diseases Unit. Her other interests include viral hepatitis in pregnancy, delta/Hepatitis B virus coinfection, and addressing the barriers to inclusion of under-served populations in clinical trials. She has worked with organisations such as the Hepatitis C Trust and BHA for Equality to promote viral hepatitis and HIV education and screening in migrant and refugee communities, and she chairs the Greater Manchester Viral Hepatitis Strategy: Migrants and Ethnic Groups sub group.



Dr Javier Vilar, Consultant in Infectious Diseases and Greater Manchester and East Cheshire Hepatitis C ODN Co-Chair, North Manchester General Hospital - Manchester University NHS Foundation Trust

Dr Javier Vilar qualified from the University of the Basque Country in Spain in 1988. He underwent postgraduate training in the UK in Middlesbrough, Manchester and Liverpool in Infectious Diseases and General Medicine. He became a consultant in Infectious Diseases in December 2000 at North Manchester General Hospital. His main area of interest is blood borne viruses and in particular strategies to promote engagement of underprivileged and vulnerable patients. He has been working as part of the steering group for the former Greater Manchester Hepatitis C strategy and now the Greater Manchester Hepatitis Strategy since their creation in 2006. He is also the co-Chair of the Greater Manchester and East Cheshire Operational Delivery Network. He is a member of Fast Track Cities for Manchester. He leads the community hepatitis test and treating network in Greater Manchester in prisons, hostels, drug services, charity organisations, GPs, probation, and community centres/clinics run by an MDT team as well as running his unit's HIV clinics in those settings. He led on the NHSE grant application for testing for Hepatitis C in the emergency departments in the city of Manchester as well as several grants for testing and treating across his ODN network.



Dr John Walsh, Consultant HIV/ Sexual Health Physician, Imperial College Healthcare NHS Trust, UK

John has been a consultant in HIV and Sexual Health at St Mary's Hospital since 2001.



Dr Laura Waters, GU/HIV consultant and HIV & hepatitis lead, The Mortimer Market Centre, London


Laura Waters is a HIV & Sexual consultant and HIV lead at The Mortimer Market Centre, London. She is chair of the British HIV Association (BHIVA) and represents BHIVA on the HIV Clinical Reference Group, advising NHS England on HIV treatment and care. She has published & presented widely, and is a trustee for the Terrence Higgins Trust and The Food Chain. She teaches regularly at local, regional and national level, including on HIV courses for University College London and the London School of Hygiene & Tropical Medicine.



Joshua Wharton, Project Coordinator, George House Trust, UK

Joshua Wharton is a Project Coordinator at George House Trust. He manages the 'Better Together' project, a mentorship programme that provides support in clinics and the community.

BHIVA 2022 Spring Conference



Exhibitors

- | | | |
|---------------------------------|----------------------------------------------------------------|-------------------------------------|
| 1. Gilead Sciences | 10. ViiV Healthcare | 17. HIV Trainee Association (HIVTA) |
| 2. Gilead Sciences | 11. HIV i-Base and UK-CAB | 18. Viartis |
| 3. Kora Healthcare | 12. National AIDS Trust | 19. Janssen |
| 4. CHIVA | 13. Mildmay Mission Hospital | 20. MSD |
| 5. Saving Lives | 14. Integrated Screening Outcomes Surveillance Service (ISOSS) | 21. Theratechnologies |
| 6. Positively UK | 15. Invitech-OraQuick | 22. NAM aidsmap |
| 7. British HIV Association | 16. UK Health Security Agency (UKHSA) | |
| 8. HIV Prevention England - THT | | |
| 9. Sophia Forum | | |

Sponsors and Exhibitors

BHIVA Platinum Sponsors and Exhibitors



Gilead Sciences Ltd
280 High Holborn
London
WC1V 7EE



MSD Ltd
120 Moorgate
London
EC2M 6UR



ViiV Healthcare UK Ltd
Stockley Park West
Uxbridge
Middlesex
UB11 1BT

BHIVA Sponsor and Exhibitor 2022



Viatrix
Building 4, Trident Place, Mosquito Way,
Hatfield AL10 9UL

BHIVA is grateful to their sponsors and commercial exhibitors for their continued support. The funds provided by sponsors and commercial exhibitors are used solely for the educational content of BHIVA events and are not allocated to BHIVA's social events.

Exhibitors



British HIV Association



Chiva



HIV i-Base UK-CAB



HIV Trainee Association (HIVTA)



Invitech-OraQuick



Integrated Screening Outcomes Surveillance Service (ISOSS)



Janssen



Kora Healthcare



Mildmay Mission Hospital



National AIDS Trust



NAM



Positively UK



Saving Lives UK



Sophia Forum UK



HIV Prevention England - THT



Theratechnologies



UKHSA
(UK Health Security Agency)



www.bhiva.org

BHIVA Stand 7

BHIVA is the leading UK association representing professionals in HIV care. Since 1995, we have been committed to providing excellent care for people living with and affected by HIV. BHIVA is a national advisory body on all aspects of HIV care and we provide a national platform for HIV care issues. Our representatives contribute to international, national and local committees dealing with HIV care. In addition, we promote undergraduate, postgraduate and continuing medical education within HIV care.



www.chiva.org.uk

CHIVA Stand 4

CHIVA carries out direct support work with children, young people and families living with HIV, and works with health professionals, to ensure that children and young people living with HIV have the treatment and care, knowledge, understanding, skills and wider support needed to live well and achieve their greatest potential. CHIVA works with people living with HIV who have transitioned to adult care up to age 25 and there are peer opportunities beyond this age too.

PLATINUM SPONSOR



www.gilead.co.uk

Gilead Sciences Stand 1 & Stand 2

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.



www.i-base.info ukcab.net

HIV i-Base UK-CAB Stand 11

HIV i-Base is a treatment activist group. We are committed to providing timely and up to date information about HIV treatment to HIV positive people and to health care professionals. This includes technical and non-technical publications (all also available online, many in other languages) and a Q&A service (by phone, email and online).

Founded in 2002, the UK Community Advisory Board (UK-CAB) is a network of 700+ treatment activists from 100+ HIV community organisations. The UK-CAB provides a unique collective community voice and expertise beyond the individual for the many clinicians, researchers and policy makers who actively seek community views.



www.hivta.org.uk

HIV Trainee Association (HIVTA) Stand 17

The HIV Trainee Association has been formed for UK-based trainees with an interest in HIV Medicine: Infectious Diseases, Genito-Urinary Medicine and General Internal Medicine who care for people living with HIV. Membership is open to SpRs/STs and Research Fellows, and those aspiring physicians in Foundation Year Two/ Internal Medicine Training. The Association acts as an educational facility, and provides all members with a national network for mutual support and advice.



www.oralhivtest.co.uk

Invitech-OraQuick Stand 15

Invitech is a trusted supplier to the NHS and public health providers across the United Kingdom. We are a privately held distribution business, founded in 2008, certified to ISO9001:2015, and representing a number of global brands. Invitech has been the UK partner of OraSure since 2012 supplying the OraQuick HIV 1/2 Antibody Test, the world's first point of care test for the detection of HIV antibodies in oral fluid. With over 75 million tests used worldwide we are delighted that the test is now available for Self-Testing and is exclusively available via Invitech. For more information visit www.oralhivtest.co.uk



www.ucl.ac.uk/isoss

Integrated Screening Outcomes Surveillance Service (ISOSS) Stand 14

The Integrated Screening Outcomes Surveillance Service (ISOSS) is part of the NHS Infectious Diseases in Pregnancy Screening Programme (IDPS). Based at UCL Great Ormond Street Institute of Child Health (GOS ICH), ISOSS carry out the national monitoring of HIV, syphilis and hepatitis B in pregnant women and children. Long-term paediatric HIV surveillance is carried out by the Children's HIV and AIDS Reporting System (CHARS) for NHS England and NHS Improvement and the UK Health Security Agency's National Infection Service. Also based at GOS ICH, CHARS follows all children and young people living with HIV who access paediatric services in England.



www.janssen.com/uk/

Janssen Stand 19

Our Work in Infectious Diseases and Vaccines At Janssen, our fight against infectious diseases is a global effort. From viral hepatitis and human immunodeficiency virus (HIV) to pathogens of global concern. We strive to discover and develop novel therapeutics and vaccines to help prevent, treat, and ultimately cure infectious diseases worldwide, improving treatment outcomes and patients' lives. With goals like these, there's no time to waste. That's why the team focuses on internal discovery and world-class development of therapeutics and vaccines whilst seeking out partnerships across the world to connect our expertise with others. We believe these problems can be conquered the same way all of humanity's greatest problems have been solved: persistent effort and game-changing innovation.



www.korahealthcare.com

Kora Healthcare Stand 3

Kora Healthcare are pleased to present selected products within our sexual health portfolio, including our warts management product Catephen® (<https://www.medicines.org.uk/emc/product/1894>), which is included in the BASHH guidelines (<https://www.bashhguidelines.org/current-guidelines/skin-conditions/anogenital-warts-2015/>) as well as our non antibiotic, broad spectrum antimicrobial and anti-infective vaginal tablet for Bacterial Vaginosis Fluomizin® (<https://www.medicines.org.uk/emc/product/1997#grf>). Please come to our stand for further information and/or email: mark.blowers@korahealthcare.com



www.mildmay.nhs.uk

Mildmay Mission Hospital Stand 13

Mildmay Mission Hospital is a charitable hospital that has been at the forefront of specialist HIV care and service provision since 1988. Mildmay began as a charitable Christian institution over 160 years ago. It has specialised in HIV for over 30, and continues to deliver quality care and treatment, prevention work, rehabilitation, training, education and health strengthening in the UK and East Africa. In 2020, Mildmay started a ground-breaking service providing step-down, rehabilitative healthcare for people who are homeless or rough-sleeping and recuperating from illness or injury. We became London's primary COVID-Care Centre for this cohort and for HIV patients.

PLATINUM SPONSOR



www.msd-uk.com

MSD Stand 20

For 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook



HIV & AIDS – sharing knowledge, changing lives

www.aidsmap.com

NAM Stand 22

NAM aidsmap works to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital in the fight against HIV & AIDS. On aidsmap.com, we publish the latest HIV news, scientific research from the world's leading HIV conferences, clear and reliable information on all aspects of HIV, broadcasts and digital media and translations and adaptations of our resources. We also offer a patient information subscription scheme, where clinics and patients can access our printed and digital booklets and leaflets, factsheets and online interactive tools.



www.nat.org.uk

National AIDS Trust Stand 12

National AIDS Trust - We are the UK's HIV rights charity. We work to stop HIV from standing in the way of health, dignity, and equality, and to end new HIV transmissions. Our expertise, research, and advocacy secure lasting change to the lives of people living with and at risk of HIV.



www.positivelyuk.org

Positively UK Stand 6

Positively UK provides peer-led support, advocacy and information to anyone living with HIV in the UK, to effectively manage any aspect of their diagnosis, care and life with HIV. Working in partnership with the NHS, we provide integrated peer support within 16 clinics across London. We offer training to people with HIV to deliver high quality and effective peer support and collaborate with clinics and voluntary organisations around the UK to establish peer support programmes. We want all people living with HIV to have access to peer-led support.



www.savinglivesuk.com

Saving Lives UK Stand 5

We are a national HIV, Hepatitis and Sexual Health Awareness Charity

Our Aims:

To deliver public health campaigns for HIV, Hepatitis and sexual health

Increase awareness

Increase testing

Normalise HIV TESTING in hospitals, GP practices and in general to the public

Helps reduce late diagnosis

Reduce transmission

Reduce stigma - through education and communication

We work to achieve this through:

- Health promotion activities
- Sharing and providing health promotion materials
- Communicating through social media and traditional media
- Providing FREE HIV postal testing kits

We will keep working until testing is routine – and anyone who needs treatment can get it.



www.sophiaforum.net

Sophia Forum UK Stand 9

Sophia Forum is a UK based Charity with a national and international reach. We promote and advocate for the rights, health, welfare and dignity of women living with and at risk of HIV through research, raising awareness and influencing policy.

Our vision:

A world where nothing stands in the way of all women living with HIV enjoying the right to a dignified, fulfilled and healthy life.

Our mission:

We exist to empower all women living with HIV to reach their full potential, and ensure their voices are heard and their needs prioritised, within the health sector and wider society.

We make sure women are meaningfully involved in all our work. Our CEO is a woman living with HIV, our one member of staff is a woman living with HIV, and our Board is also representative of women living with HIV.



www.hivpreventionengland.org.uk

HIV Prevention England - THT Stand 8

HIV Prevention England (HPE) is the national HIV prevention programme for England. It delivers a nationally co-ordinated programme of work for people working in HIV prevention and sexual health, in particular those working with gay and bisexual men, people of Black African ethnicity, and other emerging populations affected by HIV. Complementing locally commissioned activity, HPE brings together campaigns, including National HIV Testing Week, local activation partners, and a capacity and skills development programme. HPE is funded by the Office of Health Improvement and Disparities and managed by Terrence Higgins Trust.



Thera Technologies Stand 21

Thera Technologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV, oncology and NASH. Our mission is to make a real difference to the lives of patients requiring specialised therapies including those living with HIV.

For more information you can contact us on medinfo.eu@theratech.com Lowri Feeney, UK Medical Lead is available for any medical questions: lfeeney@theratech.com



**UK Health
Security
Agency**

www.gov.uk/government/organisations/uk-health-security-agency

UKHSA (UK Health Security Agency) Stand 16

The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. UKHSA is an executive agency, sponsored by the Department of Health and Social Care.

SPONSOR



www.viatris.com/en-gb/lm/united-kingdom

Viatriis Stand 18

Viatriis is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services. Formed in November 2020, Viatriis brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries. Viatriis' portfolio comprises over 1,400 approved molecules across a wide range of therapeutic areas; including globally recognized complex generic and branded medicines.

PLATINUM SPONSOR



www.viivhealthcare.com

ViiV Healthcare UK Stand 10

We are ViiV Healthcare: A specialist pharmaceutical company 100% dedicated to HIV medicines and research, and completely focused on people living with HIV and AIDS. In the last 30 years, the world of science and the HIV and AIDS community have worked together to control the HIV epidemic. Right now, we face a new wave of challenges, still... we have to keep going. We are here until HIV and AIDS aren't.

Speakers & conflicts of interest

Dr Jose Arribas

- Advisory fees, speaker fees and grant support: ViiV Healthcare, GSK, Janssen, Gilead Sciences, MSD, Aelix, Serono, Lilly, Roche

Mr Bertrand Audoin – none

Dr Chitra Babu – none

Dr Angela Bailey

- Conference registration fees received from Gilead Sciences (April 2021) and ViiV Healthcare (July 2021).

Dr Laura Byrne – none

Dr Daniela Chilton

- Speaker fees from Gilead, Jansen and ViiV Healthcare
- Advisory board fees from ViiV Healthcare and Gilead Sciences
- Receipt of grants from Gilead Sciences

Rob Cookson – none

Dr Sara Croxford – none

Dr Hilary Curtis – none

Professor Stéphane De Wit – none

Jim Fielder – none

Dr Caroline Foster – none

Professor Anna-Maria Geretti

- Roche Pharma Research & Early Development (personal fees, grant income)

Professor Yvonne Gilleece

- Recipient of honoraria, consultation fees and speakers bureau from: Gilead Sciences & ViiV Healthcare
- Recipient of research grants/support from ViiV Healthcare
- Recipient of travel sponsorship from ViiV Healthcare

Anne Glew – none

Anthony Harrison-West – none

Dr Caroline Johnson – none

Dr Howell Jones

- works as part of the Sage clinic team which is supported by an unrestricted grant from Gilead Sciences, Inc.

Professor Sebastian Lucas – none

Dr Swapna Mandal – none

Fiona Marra

- Educational Grants and/or consultation fees ViiV Healthcare, Gilead Sciences, MSD

Dr Louise Melvin – none

Ms Fungai Murau – none

Hajra Okhai – none

Professor Chloe Orkin

- Recipient of honoraria, consultation fees and speakers bureau from: Gilead Sciences, GSK, ViiV Healthcare, Janssen & MSD
- Recipient of research grants/support from: GILEAD, GSK, ViiV Healthcare, Janssen & MSD
- Recipient of travel sponsorship from: GILEAD, ViiV and GSK

Roger Paredes

- I have participated in Advisory Boards from ViiV Healthcare, MSD, Gilead Sciences, Theratechnologies, Lilly and Sobi. I have received research funds awarded to my institution from ViiV Healthcare, MSD and Gilead Sciences

Dr Dimitra Peppas – none

Professor Matt Phillips – none

Dr Erica Pool – none

Professor Dr Jürgen Rockstroh

- Honoraria for lectures and/or consultancies from Abivax, Galapagos, Gilead Sciences, Janssen, Merck, NPO Petrovax Pharm LLC, Theratechnologies and ViiV Healthcare.

Professor Caroline Sabin

- Editor-in-chief of *HIV Medicine*

Dr Whitney Scott

- Research described in the presentation given at the BHIVA Spring Conference was independent work supported by the National Institute for Health Research (NIHR Postdoctoral Fellowship, Dr Whitney Scott, PDF-2015-08-059). The views expressed are those of the presenter and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.
- Consulted for Ampersand Health (no financial compensation received)

Mr Alex Sparrowhawk – none

Grant Sugden – none

Dr Shema Tariq

- The PRIME Study was funded by the NIHR in the form of a postdoctoral fellowship to ST (PDF-2014-07-071) and a UCL/Wellcome Institutional Strategic Support Fund Flexible Support Award (204841/Z/16/Z). This PRIME FSH Study was funded by a British HIV Association Research Award

Dr Maya Tickell-Painter – none

Dr Athavan Umaipalan

- Received payment from Gilead Sciences for teaching/training sessions
- Granted use of lenacapavir through Gilead Sciences compassionate programme
- Sponsorship from ViiV Healthcare for conferences

Dr Alison Uriel

- My research interests include prophylaxis and treatment of COVID 19 but I have not received any financial support from pharmaceutical sponsors in relation to COVID research – I am currently a PI for 2 Astra Zeneca sponsored trials which I am likely to reference during my talk, but have not received any individual financial support from this company.

Dr Javier Vilar – none

Dr John Walsh – none

Dr Laura Waters

- Investigator on trials sponsored by ViiV Healthcare, Gilead Sciences & Janssen.
- Recipient of speaker fees from Gilead Sciences, ViiV Healthcare, Janssen, MSD & Mylan.
- Other educational activities in conjunction with Gilead Sciences, ViiV Healthcare, Janssen, MSD, Mylan, Cipla & Theratech.
- Member of HIV Clinical Reference Group & co-chair of HIV CRG drugs sub-group.

Joshua Wharton - none

SAVE THE DATE

2022 Autumn Conference
Friday 25th November 2022
LONDON

#BHIVA2022
Follow us on social media

